Boston/Johnson & Johnson get June 05 patent trial date
This article was originally published in Clinica
Executive Summary
The US District Court in Delaware has scheduled a trial for June 2005 in the ongoing drug-eluting stent patent infringement battle between Boston Scientific and Johnson & Johnson unit Cordis. The trial will not address all of the patents cited in the suits that the two firms filed against each other in 2003. It will involve two of the six patents that Boston claims are infringed by Cordis's Cypher sirolimus-coated stent, and the one patent that Cordis claims Boston's Express2 device infringes. Express2 is used as the platform for Boston's Taxus paclitaxel-coated stent.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.